Sipuleucel-T (Provenge (TM)): active cellular immunotherapy for advanced prostate cancer
Canadian Agency for Drugs and Technologies in Health
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
Canadian Agency for Drugs and Technologies in Health. Sipuleucel-T (Provenge (TM)): active cellular immunotherapy for advanced prostate cancer. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2007